Navigation Links
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
Date:6/8/2009

ROCKVILLE, Md., June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $33.0 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized.

In February 2009, GSK announced initiation of a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria in the long-term treatment of type 2 diabetes mellitus. All inquiries regarding the Phase 2 data presented at ADA, or about the development of Syncria, should be directed to the contacts provided by GSK. To view the GSK press release, please click here.

For more information about HGS, please direct inquiries to the HGS contacts provided, or visit the Company's web site at www.hgsi.com.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. (Nasdaq: '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., CANOGAPARK,Calif.,Nov.25/PRNewswire/--PraxisE...ntheAmericanAcademyofFamilyPhysicians,(AAFP)Family...eyforimprovingmedicalquality,healthmaintenance,and...islation.Praxisalsoranked#1amongdoctorsindicatingt...Finally,Praxisalsorankednumberoneinthecountryinpro...
(Date:11/25/2009)..., PRINCETON,N.J.,Nov.25/PRNewswire-FirstCall/--...aceuticalcompanycommittedtodiscovering,developinga...reportedfinancialresultsforthefiscalyearendedSepte...illionincash,cashequivalentsandshortterminvestment...RG7128 ,, Phase2bTrial ,, InlateNovembe...
(Date:11/25/2009)..., BRIDGEWATER,N.J.,Nov.25/PRNewswire/--TheFDAgr...ine)tablets,anon-nucleosidereversetranscriptaseinh...ndicatedforuseintreatment-experiencedadultswhoaree...nttoanNNRTIandotherantiretroviral(ARV)agents.Thetr...studiesknownasDUET-1andDUET-2.INTELENCEiscurrently...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4VA Secretary Addresses 65th Annual AMVETS Convention 54464 1VA Secretary Addresses 65th Annual AMVETS Convention 54464 2VA Secretary Addresses 65th Annual AMVETS Convention 54464 3VA Secretary Addresses 65th Annual AMVETS Convention 54464 4Bone Safety 101 54462 1Bone Safety 101 54462 1
(Date:11/26/2009)... a bigger thrill when on an emotional rollercoaste...althDay News) -- Call it the fear factor meets the...at spectators -- especially those who root for the...f it,s a closely contested match and victory was i...air. , Chew on that this Thanksgiving weekend a...
(Date:11/26/2009)... Benton Communications announces ...wth system for retailers struggling to make an eco... November 26, 2009 -- Flu fears is the type of cha... emergency room, according to Dr. David Benton, bu...sed business growth system – The Rfactor In...
(Date:11/25/2009)...EMERYVILLE,Calif.,Nov.25/PRNewswire-FirstCall/-- ...cedthatthecompanywillhosttwoinvestoreventsinDecemb...:00a.m.CT/10:00a.m.ET ,, Principalinvestigato...ibinrelapsedand/orrefractorymultiplemyeloma,asfeat...lMeetingandExpositioninNewOrleans,LA.Theteleconfer...
(Date:11/25/2009)...SILVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--An...erforDrugEvaluationandResearch,titled"ADifficultBa...intheNov.26,2009issueofTheNewEnglandJournalofMedic...rnh/20090824/FDALOGO ) ,, Inthearticle,Woodcock...painmedicationforthosewhoneeditandmanagingtherisks...
(Date:11/25/2009)...erm survivors of testicular cancer who were treate...e side effects, including neurological side effect...t treated with chemotherapy, according to a new st...f the National Cancer Institute . , Marianne Bry... University Hospital, in Bergen, Norway, and colle...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...L. Myers, President, Campaign for Tobacco-Free Ki...ment of Matthew L. Myers, President, Campaign for ...r Latin America and the world, both the,Mexico Cit...Federal District Legislative Assembly (ALDF) appro...
...esearchers at Mayo Clinic and the Virginia Bioinfo...nt from the National Institute of Allergy and Infe...f the role of environmental fungi in chronic airwa...ntal fungus Alternaria triggers airway inflammatio...
... Feb. 27 Versus,Technology, Inc. ("Versus" or the...ts first fiscal quarter ended January 31, 2008, a ...ame quarter of the prior,year. Versus, quarterly r... are not necessarily indicative of what full,year ...
...us Americans Driving Dental Implant and Facial ...search Group, WALTHAM, Mass., Feb. 27 According ...re Volumes 2008 report, dental implants,and facial...h are only growing at CAGRs of under 5%. Aesthetic...
...ference Call on Tuesday, March 4th at 2:00 pm ET -.... (Amex: HH ) today announced that it will host a...uesday, March 4th at 2:00 pm ET. The,Company,s new...recent leadership,transition and near-term operati...
..., Feb. 27 John Miller, Chief,Executive Officer of...recent appointment of Nancy Frost as the Vice Pres...CA-based insurance intermediary and broker., Addr...ployee Benefits arena. She has spent over twenty y...
Other Medicine News:Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 2Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 3Health News:VBI, Mayo Clinic investigate link between fungal proteins, innate immunity and asthma 2Health News:VBI, Mayo Clinic investigate link between fungal proteins, innate immunity and asthma 3Health News:Versus Technology Announces First Quarter Results 2Health News:Versus Technology Announces First Quarter Results 3Health News:Versus Technology Announces First Quarter Results 4Health News:Versus Technology Announces First Quarter Results 5Health News:Versus Technology Announces First Quarter Results 6Health News:Cosmetic Procedures Outpace All Other Surgical Procedures 2Health News:Hooper Holmes to Provide Business Update 2Health News:Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President 2
1.0 mm Micro System
Grafton DBM Matrix PLF
Optium DBM Gel, TGEL05
...w generation Endoalpha is a centralized O.R. contr...urse by giving them better control, better informa...protection against obsolescence, as future enhance... than the purchase of an entirely new system. Endo...
Medicine Products: